RSS Comments RSS

Posts Tagged ‘SLE’

Drug-Induced Lupus is Reversible

Sunday, November 15th, 2009

lupus symptomsThe drugs most frequently associated with drug-induced lupus are:

Chlorpromazine, Hydralazine, Isoniazid, Methyldopa, Penicillamine, Procainamide, Quinidine,  and Sulfasalazine. Currently, newer medications have been associated with drug-induced lupus, such as the new biological agents used to treat rheumatoid arthritis, etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira). Typically, once the suspected medication is stopped, symptoms should decline within days, usually symptoms disappear after one or two weeks. Drug-induced lupus can be diagnosed with certainty only by resolution of symptoms and their failure to recur after stopping the medication.

Drug-induced lupus erythematosus resembles systemic lupus erythematosus (SLE). It results from a hypersensitivity reaction to a medication. The drug may react with cell materials, causing the body to form antibodies that attack the body’s own healthy cells. Symptoms tend to occur after taking the drug for at least 3 to 6 months. Persons with drug-induced lupus erythematosus may have symptoms that affect the joints (arthritis), heart, and lungs. Other symptoms associated with SLE, such as lupus nephritis and neurological disease, are rare. Drug-induced lupus affects men and women equally.

First Lupus Drug in Decades to Show Effectiveness

Monday, July 20th, 2009

What has been described as the first lupus drug in decades to show effectiveness in clinical trials, the announcement that Benlysta (belimumab) outperformed placebo has come as a surprised, where many had assumed the drug was going nowhere.

Earlier today, the Lupus Research Institute (LRI) and its National Coalition of state and local organizations congratulated Human Genome Sciences Inc (HGS) and GlaxoSmithKline (GSK) on what they described as the “highly promising results” of the late stage trial of their experimental drug to treat people with systemic lupus.

Benlysta (belimumab) is the first investigational human monoclonal antibody in a class called “BLyS-specific inhibitors” and is being developed by HGS and GSK under a co-development and commercialization agreement that they signed in August 2006.

BLyS-specific inhibitors recognize and inhibit the biological activity of B-lymphocyte stimulators.

Systemic lupus erythematosus (SLE) or lupus, is a chronic and sometimes fatal autoimmune disorder that not many people know about, although it affects more than 1.5 million Americans, mostly women of childbearing age. It is a leading cause of premature cardiovascular disease, kidney disease and stroke among young women, says the LRI.

The disease causes production of antibodies that attack nearly every healthy organ and tissue of the body, including kidneys, brain, heart, lungs, skin, blood and joints. The last time a treatment was approved was nearly 50 years ago, and many of the drugs currently used are nearly as toxic as the disease itself.

Support Lupus Awareness